Long-Term Clinical Outcomes and Factors Predictive of Relapse After 5-Aminosalicylate or Sulfasalazine Therapy in Patients With Intestinal Behcet Disease
Journal of Clinical Gastroenterology, 04/26/2012
Jung YS et al. – The study has shown that 5–aminosalicylic acid (5–ASA)/sulfasalazine therapy has a positive effect in maintaining remission in patients with intestinal BD. However, a younger age (<35 y), higher C–reactive protein level (≥1.5 mg/dL), and a higher disease activity index for intestinal Behcet disease score (≥60) were associated with a poor response to 5–ASA/sulfasalazine therapy, making careful observation and intensive treatment necessary in these risk groups.